NRC
NRC Health
NasdaqGSUSDEQUITY
DELAYED
Last price
22.19
▲ 0.37 (1.70%)
MARKET · —
Price
Open
21.81
Prev close
21.82
Day high
22.50
Day low
21.73
Volume
230.42K
Market cap
—
P/E (TTM)
—
52W range
11.01 – 23.68
Trailing performance
Returnvs SPY
1W
+4.72%
+6.1%
1M
+6.53%
+2.8%
3M
+16.54%
+13.4%
6M
+62.33%
+51.3%
YTD
+18.22%
+5.9%
1Y
+41.16%
+21.2%
3Y
-48.57%
-122.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
21.52
+3.13% from price
SMA 20
20.70
+7.22% from price
SMA 50
20.80
+6.67% from price
SMA 100
19.53
+13.64% from price
SMA 200
18.24
+21.68% from price
EMA 12
21.40
+3.67% from price
EMA 26
21.06
+5.38% from price
EMA 50
20.64
+7.51% from price
RSI (14)
60.0
Neutral
MACD (12,26,9)
0.35
Hist 0.20
ATR (14)
0.97
4.38% of price
Realised vol 30D
67.0%
Annualised
Bollinger upper
23.07
20, 2σ
Bollinger lower
18.32
20, 2σ
50 / 200 cross
Golden
20.80 vs 18.24
Trend bias
Above 200
+21.68%
Risk profile
Beta vs SPY
0.61
Less volatile than market
Correlation to SPY
0.14
Largely independent
Realised vol 30D
67.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-46.5%
Peak to trough
Max drawdown 5Y
-81.4%
Peak to trough
ATR 14
0.97
4.38% of price
Beta (reported)
—
5Y monthly, from filing
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Resideo Technologies Names New CFO
MT Newswires · 10d ago
Resideo Appoints Shane Harrison as Chief Financial Officer
PR Newswire · 10d ago
Record Backlog Powers NRC Health’s (NRC) Upward Potential
Insider Monkey · 12d ago
NRC Down 8% Despite Q2 Earnings Rising Y/Y on TRCV Growth
Zacks · 19d ago
New NRC Health Research Reveals What Drives Patient Loyalty Beyond Access
Business Wire · 23d ago
NRC Health (NRC) Q2 2026 Earnings Call Highlights: Strong TRCV Growth Amid Market Uncertainty
GuruFocus.com · 25d ago
National Research Q2 Earnings Call Highlights
MarketBeat · 25d ago
National Research: Q2 Earnings Snapshot
Associated Press · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.